Impact of baseline symptom severity on future risk of benign prostatic hyperplasia-related outcomes and long-term response to finasteride
| Autor: | Pratap K. Reddy, Steven Rosenberg, Richard Milsten, Michael W. Lee, M. A. X. Koppel, Patricia Gilhooly, Richard F. Labasky, Steven A. Kaplan, Joanne Waldstreicher, Charles D. White, Dennis Garvin, Frances Pappas, David Sussman |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class business.industry Urinary retention Urology Incidence (epidemiology) Hyperplasia urologic and male genital diseases Antiandrogen medicine.disease Placebo law.invention Surgery chemistry.chemical_compound medicine.anatomical_structure Randomized controlled trial chemistry law Prostate medicine Finasteride medicine.symptom business |
| Zdroj: | Urology. 56:610-616 |
| ISSN: | 0090-4295 |
| Popis: | Objectives. To evaluate the long-term effects of finasteride on symptoms, acute urinary retention (AUR), and the need for benign prostatic hyperplasia (BPH)-related surgery in relationship to baseline symptom severity. Methods. A total of 3040 men with BPH were treated for 4 years with finasteride or placebo. The changes from baseline in symptoms and the incidence of BPH-related surgery and AUR were determined in men with mild (less than 8), low-moderate (8 to 12), high-moderate (13 to 19), and severe (greater than 19) baseline quasi-American Urological Association symptoms for all patients and for the subgroup with a baseline prostate-specific antigen (PSA) level of 1.4 ng/mL or greater. Results. In patients who completed the 4-year study, the change in symptom score, stratified by baseline symptom severity, was +1.4 ± 0.5 (mild), −0.8 ± 0.3 (low-moderate), −3.6 ± 0.3 (high-moderate), and −7.7 ± 0.5 (severe) in finasteride-treated patients and, respectively, +3.4 ± 0.5, +0.7 ± 0.3, −1.4 ± 0.3, and −5.3 ± 0.6 in placebo-treated patients (between-group P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect